GlassScriptPhysician profile
Wei Zhao
NPI 1386928281
$9,961.81
in general payments reported to CMS, 2019-2025
44 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $1,038 · 2021: $810 · 2022: $1,539 · 2023: $1,774 · 2024: $1,914 · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,499 · Education: $43.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,498.58 |
| Education | $43.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,399.11 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Novo Nordisk INC | $1,300.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,069.97 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $862.20 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $825.77 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $652.18 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $596.25 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $534.12 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $412.49 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $332.82 | 2019-2025 | Capvaxive, Verquvo, Steglatro |
| Amgen INC. | $272.89 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $186.85 | 2019-2023 | |
| Glaxosmithkline, LLC. | $157.38 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Allergan, INC. | $148.03 | 2019-2020 | |
| Stryker Corporation | $131.50 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.